Merck said it has pushed back regulatory plans for an experimental cardiovascular pill that has been hailed by some as a possible follow-on to blockbuster cholesterol drug Zocor.The company will not ...

NEW YORK (MarketWatch) - Merck & Co. on Friday said it revised the filing timeline for its investigational treatment in development for atherosclerosis, or MK-0524B. The Whitehouse Station, NJ-based ...

Squaring off against Pfizer in the next-gen pneumococcal vaccine field, Merck has posted two more positive phase 3 trials and now says it's planning an FDA filing yet this year. That timing matches ...

Merck & Co., Inc. MRK announced FDA approval for its Keytruda as a monotherapy for first-line treatment of patients with stage 3 non-small cell lung cancer, who cannot undergo surgery or ...